Search is Powered by Google
Cancer / Oncology News

Hope For Early Cancer Detection With Improved Understanding Of Disease's First Stages

Main Category: Cancer / Oncology
Also Included In: Genetics
Article Date: 04 Oct 2007 - 2:00 PST

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article


Current Article Ratings:

Patient / Public:4 stars

4 (1 votes)

Health Professional:not yet rated

Article Opinions: 0 posts

A test to detect the very early stages of cancer could one day result from new research by Cardiff University scientists.

A team at the University's School of Medicine has just published a study on telomeres -- small structures at the end of human chromosomes which can play a crucial part in the onset of cancer.

Telomeres control cell division in the body -- by gradually becoming shorter they can tell cells when it is time to stop dividing. However when telomeres stop working properly, they can cause the cells to mutate and start dividing uncontrollably, which can lead to the formation of tumours.

The Cardiff study used ground-breaking techniques to study telomeres in human cells. The researchers found the critical length at which telomeres stop working and also that some telomeres can be shortened or deleted at random, without any external cause.

The researchers also discovered how chromosomes can fuse together once they lose the protection of their telomeres. Chromosomal fusion causes the chromosomes to disintegrate, which can result in the development of cancerous growths. The Cardiff study means there is now a system which can detect chromosomal fusions from single DNA molecules, opening up the possibility of an "early-warning" test for cancer.

Project leader Dr Duncan Baird, of the School of Medicine's Department of Pathology, said: "This study threw up a number of significant results. The fact that telomeres can be deleted at random in otherwise normal cells indicates that some of the earliest cancerous changes can be initiated without any obvious extraneous influence. Our long-term aim with this research is to develop a clinical test to pick up these events. The fact we can now detect chromosome fusions at the single molecule level offers hope that we will be able to achieve it."

Dr Lesley Walker, director of cancer information at Cancer Research UK, which funded the research, said: "Dr Baird and his team are making great strides in increasing our understanding of the very earliest stages of cancer by looking at these changes in single cells. It remains to be seen whether they can translate their technique and findings into a reliable test for early cancers."

----------------------------
Article adapted by Medical News Today from original press release.
----------------------------

The research has just been published in the leading international journal Genes and Development.

Source: Stephen Rouse
Cardiff University




Personalized Homepage Weekly Newsletters Daily News Alerts
Opioid Induced Constipation ADHD Anxiety Asthma Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles All 'How To...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
Understanding And Treating Triple-Negative Breast Cancer
07 Jan 2009
Triple-negative breast cancer is a subtype of breast cancer that is clinically negative for expression of estrogen and progesterone receptors (ER/PR) and HER2 protein. It is characterized by its unique molecular profile...


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

View more videos...